Compare MTRX & FHTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | MTRX | FHTX |
|---|---|---|
| Founded | 1984 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Engineering & Construction | Medicinal Chemicals and Botanical Products |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 344.9M | 323.4M |
| IPO Year | 1995 | 2020 |
| Metric | MTRX | FHTX |
|---|---|---|
| Price | $13.47 | $4.81 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 8 |
| Target Price | ★ $17.00 | $11.50 |
| AVG Volume (30 Days) | ★ 134.7K | 110.0K |
| Earning Date | 05-06-2026 | 05-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 25.32 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $769,286,000.00 | $30,909,000.00 |
| Revenue This Year | $19.75 | $8.89 |
| Revenue Next Year | $7.96 | $20.13 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | 5.64 | ★ 36.75 |
| 52 Week Low | $9.88 | $3.27 |
| 52 Week High | $16.11 | $6.95 |
| Indicator | MTRX | FHTX |
|---|---|---|
| Relative Strength Index (RSI) | 75.93 | 42.62 |
| Support Level | $12.27 | $4.44 |
| Resistance Level | $14.64 | $5.82 |
| Average True Range (ATR) | 0.45 | 0.27 |
| MACD | 0.11 | -0.03 |
| Stochastic Oscillator | 87.50 | 13.54 |
Matrix Service Co provides engineering, fabrication, construction, maintenance, and repair services prominently to the energy and industrial markets. The company operates through three main segments: Storage and Terminal Solutions, Utility and Power Infrastructure, and Process and Industrial Facilities. These segments cover services like building and maintaining storage tanks and terminals, supporting power delivery and new power generation projects including renewables, as well as plant maintenance and turnarounds for refining and petrochemical industries. Matrix generates revenue by delivering these services to clients in oil, gas, power, and petrochemical sectors across North America and internationally.
Foghorn Therapeutics Inc is a clinical stage, precision therapeutics biotechnology company focused on pioneering a new class of medicines that treat serious diseases by correcting abnormal gene expression through selectively targeting the chromatin regulatory system. Its proprietary platform is designed to provide an integrated, mechanistic understanding of interactions within the chromatin regulatory system, supporting the identification and validation of potential therapeutic targets. The company's flagship program is FHD-909.